Mirtazapine for Obsessive-Compulsive Disorder: An Open Trial Followed by Double-Blind Discontinuation
The DOI matches its Crossref record.
Abstract
Article AbstractBackground: Many patients with obsessive-compulsive disorder (OCD) experience little response to standard treatment with serotonin reuptake inhibitors. Mirtazapine enhances serotonergic function by a mechanism distinct from reuptake inhibition. Because a pilot study suggested effectiveness of mirtazapine in OCD, we conducted a controlled trial. Method: We recruited 30 subjects, 15 treatment-naive and 15 treatment-experienced, with DSM-IV OCD of > = 1 year's duration and a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of > = 20. In the 12-week, open-label phase, subjects received mirtazapine starting at 30 mg/day and titrated over 2 weeks as tolerated to 60 mg/day. At week 12, responders (YBOCS score decrease > 25%) were randomly assigned, double-blind, to continue mirtazapine or switch to placebo for 8 weeks, including a 1-week, double-blind taper week for placebo subjects. Results: In the open-label phase, the mean ± SD YBOCS score fell from 28.3 ± 3.7 to 20.3 ± 8.5 (paired samples t = 4.81, p < .0001). Four subjects (13.3%) discontinued for side effects. Sixteen subjects (53.3%) (8 treatment-naive, 8 treatment-experienced) were responders and 15 agreed to randomization. Response was independent of comorbid mood disorders. In the 8-week, double-blind, placebo-controlled discontinuation phase, the mirtazapine group's mean YBOCS score fell a mean ± SD of 2.6 ± 8.7 points while the placebo group's mean score rose a mean ± SD of 9.1 ± 7.5 points (Mann Whitney U = 6.5, p = .005, 1-tailed). All other outcome measures were consistent with mirtazapine's superiority versus placebo. Conclusion: Mirtazapine may be an effective pharmacotherapy for OCD. If our results are replicated, larger double-blind studies would be indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Pallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408
“For this reason, Koran et al. (2005b) performed a follow-up study that involved 15 treatment-naive patients (mean Y-BOCS score of 27.8) diagnosed with OCD>1 year treated with mirtazapine (mean dose: 54 mg/day) in a 12-week open-label trial.”
BackgroundMethodInfluentialEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Metadata
- Authors
- Koran, L. M., Gamel, N. N., Choung, H. W., Smith, E. H., & Aboujaoude, E. N.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-04-15
- Volume
- 66
- Issue
- 04
- Pages
- 515-520
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W4313371589
- Cited by
- 82
- References
- 0
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mirtazapine for Obsessive-Compulsive Disorder: An Open Trial Followed by Double-Blind Discontinuation. https://app.cochat.ai/papers/10.4088/jcp.v66n0415
- The paper
- Koran, L. M., Gamel, N. N., Choung, H. W., Smith, E. H., & Aboujaoude, E. N. (2005). Mirtazapine for Obsessive-Compulsive Disorder: An Open Trial Followed by Double-Blind Discontinuation. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n0415
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.